NewAmsterdam Pharma's obicetrapib lowers LDL-C in Phase 3 trials, showing promise as a CETP inhibitor. Read more on NAMS ...

浙江大学医学院王英杰研究员、康博助理研究员、陈文洁博士等在 Stem Cell Research & Therapy 期刊发表了题为： OCT4 translationally promotes AKT signaling as an ...